{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:39:28Z","timestamp":1774265968844,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,4,22]],"date-time":"2010-04-22T00:00:00Z","timestamp":1271894400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10198-010-0243-5","type":"journal-article","created":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T09:17:33Z","timestamp":1271841453000},"page":"253-261","source":"Crossref","is-referenced-by-count":14,"title":["Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece"],"prefix":"10.1007","volume":"12","author":[{"given":"Nikos","family":"Maniadakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Ekman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Fragoulakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Papagiannopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Yfantopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,22]]},"reference":[{"key":"243_CR1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0025-7125(05)70568-X","volume":"81","author":"J He","year":"1997","unstructured":"He, J., Whelton, P.K.: Epidemiology and prevention of hypertension. Med. Clin. North Am. 81, 1077\u20131097 (1997)","journal-title":"Med. Clin. North Am."},{"key":"243_CR2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","volume":"360","author":"M Ezzati","year":"2002","unstructured":"Ezzati, M., Lopez, A.D., Rodgers, A., Vander Hoorn, S., Murray, C.J.: Selected major risk factors and global and regional burden of disease. Lancet 360, 1347\u20131360 (2002)","journal-title":"Lancet"},{"key":"243_CR3","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","volume":"21","author":"World Health Organization, International Society of Hypertension Writing Group","year":"2003","unstructured":"World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 21, 1983\u20131992 (2003)","journal-title":"J. Hypertens."},{"key":"243_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"P Kearney","year":"2005","unstructured":"Kearney, P., Whelton, M., Reynolds, K., Muntner, P., Whelton, P., Jiang, H.E.: Global burden of hypertension analysis of worldwide data. Lancet 365, 217\u2013223 (2005)","journal-title":"Lancet"},{"key":"243_CR5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00005650-200106000-00008","volume":"39","author":"TA Hodgson","year":"2001","unstructured":"Hodgson, T.A., Cai, L.: Medical care expenditures for hypertension, its complications, and its comorbidities. Med. Care 39, 599\u2013615 (2001)","journal-title":"Med. Care"},{"key":"243_CR6","first-page":"810","volume":"19","author":"B Sanjeev","year":"2006","unstructured":"Sanjeev, B., Thomas, J.: Incremental expenditure of treating hypertension in the United States. AJH 19, 810\u2013816 (2006)","journal-title":"AJH"},{"key":"243_CR7","first-page":"1462","volume":"28","author":"The Task force on the management of arterial hypertension of the European Society of Hypertension (ESH)and the European Society of Cardiology (ESC)","year":"2007","unstructured":"The Task force on the management of arterial hypertension of the European Society of Hypertension (ESH)and the European Society of Cardiology (ESC): 2007 Guidelines for the management of arterial hypertension. Eur. Heart J. 28, 1462\u20131536 (2007)","journal-title":"Eur. Heart J."},{"key":"243_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00019053-200624040-00008","volume":"24","author":"AH Anis","year":"2006","unstructured":"Anis, A.H., Sun, H., Singh, S., Woolcott, J.: A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. PharmacoEconomics. 24, 387\u2013400 (2006)","journal-title":"PharmacoEconomics."},{"key":"243_CR9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.clinthera.2007.05.014","volume":"29","author":"C Boersma","year":"2007","unstructured":"Boersma, C., Carides, G.W., Atthobari, J., Voors, A., Jstma, M.: An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy results from the Losartan Intervention for endpoint reduction (LIFE) study adapted to The Netherlands. Clin. Ther. 29, 963\u2013971 (2007)","journal-title":"Clin. Ther."},{"key":"243_CR10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00019053-200624060-00003","volume":"24","author":"GW Carides","year":"2006","unstructured":"Carides, G.W., Shahinfar, S., Dasbach, E.J.: The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. PharmacoEconomics 24, 549\u2013558 (2006)","journal-title":"PharmacoEconomics"},{"key":"243_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3111\/200508131138","volume":"8","author":"L Jonsson","year":"2005","unstructured":"Jonsson, L., Carides, G.W., Burke, T.A., Brandt, A.S., Salonen, T., Schon, S.: Cost-effective prevention of renal failure in type 2 diabetics using losartan. J. Med. Econ. 8, 131\u2013138 (2005)","journal-title":"J. Med. Econ."},{"key":"243_CR12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10557-005-5064-x","volume":"18","author":"TD Szucs","year":"2004","unstructured":"Szucs, T.D., Burnier, M., Erne, P.: Cost-effectiveness of losartan versus atenolol in treating hypertension an analysis of the LIFE study from a Swiss perspective. Cardiovasc. Drugs Ther. 18, 391\u2013397 (2004)","journal-title":"Cardiovasc. Drugs Ther."},{"key":"243_CR13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.curtheres.2005.12.005","volume":"66","author":"J Vora","year":"2005","unstructured":"Vora, J., Carides, G., Robinson, P.: Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus a retrospective cost-effectiveness analysis in the United Kingdom. Curr. Ther. Res. Clin. Exp. 66, 475\u2013485 (2005)","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"243_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/08037050510008940","volume":"14","author":"E Linjer","year":"2005","unstructured":"Linjer, E., Hedner, T., J\u00f6nsson, B., Tord, E., Lindholm, H.L., Dahl\u00f6f, B., Ulf de Faire, Scherst\u00e9n, B.: Cost analysis of different pharmacological treatment strategies in elderly hypertensives. Blood Press. 14, 107\u2013113 (2005)","journal-title":"Blood Press."},{"key":"243_CR15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/01.hjh.0000173527.73179.f5","volume":"23","author":"B Jonsson","year":"2005","unstructured":"Jonsson, B., Carides, G., Burke, T., Dasbach, E., Lindholm, L., Dahlof, B., the LIFE Study Group: Cost effectiveness of losartan in patients with hypertension and LVH an economic evaluation for Sweden of the LIFE trial. J. Hypertens. 23, 1425\u20131431 (2005)","journal-title":"J. Hypertens."},{"key":"243_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.jhh.1001939","volume":"20","author":"G McInnes","year":"2006","unstructured":"McInnes, G., Burke, T.A., Carides, G.: Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. J. Hum. Hypertens. 20, 51\u201358 (2006)","journal-title":"J. Hum. Hypertens."},{"key":"243_CR17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2165\/00003495-200464090-00011","volume":"64","author":"KF Croom","year":"2004","unstructured":"Croom, K.F., Curran, M.P., Goa, K.L., Perry, C.M.: Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 64, 999\u20131028 (2004)","journal-title":"Drugs"},{"key":"243_CR18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.amjhyper.2005.06.009","volume":"18","author":"G Bobrie","year":"2005","unstructured":"Bobrie, G., Delonca, J., Moulin, C., Giacomino, A., Postel-Vinay, N., Asmar, R.: A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am. J. Hypertens. 18, 1482\u20131488 (2005)","journal-title":"Am. J. Hypertens."},{"key":"243_CR19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/147323000503300603","volume":"33","author":"JM Neutel","year":"2005","unstructured":"Neutel, J.M., Smith, D.: Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan\/hydrochlorothiazide and losartan\/hydrochlorothiazide in patients with mild-to-moderate hypertension. J. Int. Med. Res. 33, 620\u2013631 (2005)","journal-title":"J. Int. Med. Res."},{"key":"243_CR20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1524-6175.2006.05676.x","volume":"8","author":"MJ Neutel","year":"2006","unstructured":"Neutel, M.J., Franklin, S.S., Oparil, S., Bhaumik, A., Ptaszynska, A., Lapuerta, P.: Efficacy and safety of irbesartan\/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J. Clin. Hypertens (Greenwich) 8, 850\u2013857 (2006)","journal-title":"J. Clin. Hypertens (Greenwich)"},{"key":"243_CR21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1524-6175.2004.03808.x","volume":"6","author":"CM Salerno","year":"2004","unstructured":"Salerno, C.M., Demopoulos, L., Mukherjee, R., Gradman, A.H.: Combination angiotensin receptor blocker\/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J. Clin. Hypertens (Greenwich) 6, 614\u2013620 (2004)","journal-title":"J. Clin. Hypertens (Greenwich)"},{"key":"243_CR22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1524-6175.2004.04720.x","volume":"7","author":"JM Neutel","year":"2005","unstructured":"Neutel, J.M., Saunders, E., Bakris, G.L., Cushman, W.C., Ferdinand, K.C., Ofili, E.O., et al.: The efficacy and safety of low- and high-dose fixed combinations of irbesartan\/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J. Clin. Hypertens (Greenwich) 7, 578\u2013586 (2005)","journal-title":"J. Clin. Hypertens (Greenwich)"},{"key":"243_CR23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/ndt\/gfh802","volume":"20","author":"JA Palmer","year":"2005","unstructured":"Palmer, J.A., Tucker, M.D., Valentine, J.W., Roze, S., Gabriel, S., Cordonnier, J.D.: Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol. Dial. Transplant. 20, 1103\u20131109 (2005)","journal-title":"Nephrol. Dial. Transplant."},{"key":"243_CR24","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.clinthera.2007.07.029","volume":"29","author":"D Coyle","year":"2007","unstructured":"Coyle, D., Rodby, R., Soroka, S., Levin, A.: Cost-effectiveness of irbesartan 300\u00a0mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clin. Ther. 29, 1508\u20131523 (2007)","journal-title":"Clin. Ther."},{"key":"243_CR25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10198-006-0033-2","volume":"8","author":"AJ Palmer","year":"2007","unstructured":"Palmer, A.J., Valentine, W.J., Ray, J.A.: Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. Eur. J. Health Econ. 8, 161\u2013168 (2007)","journal-title":"Eur. J. Health Econ."},{"key":"243_CR26","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1742-1241.2007.01343.x","volume":"61","author":"AJ Palmer","year":"2007","unstructured":"Palmer, A.J., Valentine, W.J., Ray, J.A.: Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. Int. J. Clin. Pract. 61, 1626\u20131633 (2007)","journal-title":"Int. J. Clin. Pract."},{"key":"243_CR27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1185\/030079906X132730","volume":"22","author":"AJ Palmer","year":"2006","unstructured":"Palmer, A.J., Valentine, W.J., Tucker, D.M., Ray, J.A.: A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Curr. Med. Res. Opin. 22, 2095\u20132100 (2006)","journal-title":"Curr. Med. Res. Opin."},{"key":"243_CR28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/jhh.2008.76","volume":"22","author":"M Ekman","year":"2008","unstructured":"Ekman, M., Bienfait-Beuzon, C., Jackson, J.: Cost-effectiveness of irbesartan\/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. J. Hum. Hypertens. 22, 845\u2013855 (2008)","journal-title":"J. Hum. Hypertens."},{"issue":"1","key":"243_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/hy1201.097199","volume":"39","author":"JR Glynn","year":"2002","unstructured":"Glynn, J.R., L\u2019Italien, J.G., Sesso, D.H., Jackson, A.E., Buring, E.J.: Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 39(1), 105\u2013110 (2002)","journal-title":"Hypertension"},{"key":"243_CR30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E.L., Meier, P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958)","journal-title":"J. Am. Stat. Assoc."},{"key":"243_CR31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0002-8703(00)90076-0","volume":"139","author":"ES Ford","year":"2000","unstructured":"Ford, E.S., Giles, W.H., Croft, J.B.: Prevalence of nonfatal coronary heart disease among American adults. Am. Heart J. 139, 371\u2013377 (2000)","journal-title":"Am. Heart J."},{"key":"243_CR32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1009884820941","volume":"5","author":"WB Kannel","year":"2000","unstructured":"Kannel, W.B.: Incidence and epidemiology of heart failure. Heart Fail. Rev. 5, 167\u2013173 (2000)","journal-title":"Heart Fail. Rev."},{"key":"243_CR33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0002-8703(91)90225-7","volume":"121","author":"WB Kannel","year":"1991","unstructured":"Kannel, W.B., Belanger, A.J.: Epidemiology of heart failure. Am. Heart J. 121, 951\u2013957 (1991)","journal-title":"Am. Heart J."},{"key":"243_CR34","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","volume":"106","author":"DM Lloyd-Jones","year":"2002","unstructured":"Lloyd-Jones, D.M., Larson, M.G., Leip, E.P., Beiser, A., D\u2019Agostino, R.B., Kannel, W.B., et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 106, 3068\u20133072 (2002)","journal-title":"Circulation."},{"key":"243_CR35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1388-9842(00)00115-X","volume":"3","author":"M Mejhert","year":"2001","unstructured":"Mejhert, M., Persson, H., Edner, M., Kahan, T.: Epidemiology of heart failure in Sweden\u2014a national survey. Eur. J. Heart Fail. 3, 97\u2013103 (2001)","journal-title":"Eur. J. Heart Fail."},{"key":"243_CR36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1468-1331.2006.01138.x","volume":"13","author":"T Truelsen","year":"2006","unstructured":"Truelsen, T., Piechowski-Jozwiak, B., Bonita, R., Mathers, C., Bogousslavsky, J., Boysen, G.: Stroke incidence and prevalence in Europe: a review of available data. Eur. J. Neuro. 13, 581\u2013598 (2006)","journal-title":"Eur. J. Neuro."},{"key":"243_CR37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ije\/dyh249","volume":"33","author":"T Psaltopoulou","year":"2004","unstructured":"Psaltopoulou, T., Orfanos, P., Naska, A., Lenas, D., Trichopoulos, D., Trichopoulou, A.: Prevalence, awareness, treatment and control of hypertension in a general population sample of 26, 913 adults in the Greek EPIC study. Int. J. Epidemiol. 33, 1345\u20131352 (2004)","journal-title":"Int. J. Epidemiol."},{"key":"243_CR38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.amjhyper.2005.07.011","volume":"19","author":"AD Efstratopoulos","year":"2006","unstructured":"Efstratopoulos, A.D., Voyaki, S.M., Baltas, A.A., Vratsistas, F.A., Kirlas, D.E., Kontoyannis, J.T., Sakellariou, J.G., Triantaphyllou, G.B., Alokrios, G.A., Lianas, D.N., Vasilakis, E.A., Fotiadis, K.N., Kastritsea, E.E.: Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the hypertension study in general practice in Hellas (HYPERTENSHELL) national study. Am. J. Hypertens. 19, 53\u201356 (2006)","journal-title":"Am. J. Hypertens."},{"key":"243_CR39","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1185\/030079904X5599","volume":"20","author":"VG Athyros","year":"2004","unstructured":"Athyros, V.G., Mikhailidis, D.P., Papageorgiou, A.A., Didangelos, T.P., Ganotakis, E.S., Symeonidis, A.N., Daskalopoulou, S.S., Kakafika, A.I., Elisaf, M., the METS-GREECE Collaborative Group: Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METSGREECE Multicentre Study. Curr. Med. Res. Opin. 20, 1691\u20131701 (2004)","journal-title":"Curr. Med. Res. Opin."},{"key":"243_CR40","first-page":"55","volume":"48","author":"DP Panagiotakos","year":"2007","unstructured":"Panagiotakos, D.P., Fitzgeralns, A.P., Pitsavos, P., Pipilis, A., Graham, A., Stefanadis, C.: Statistical Modelling of 10-year fatal cardiovascular disease in Greece: The HellenicSCORE (a Calibration of the ESC SCORE Project. Hellenic J. Cardiol. 48, 55\u201363 (2007)","journal-title":"Hellenic J. Cardiol."},{"key":"243_CR41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstr\u00f6m","year":"2001","unstructured":"Burstr\u00f6m, K., Johannesson, M., Diderichsen, F.: Swedish population health-related quality of life results using the EQ-5D. Qual. Life Res. 10, 621\u2013635 (2001)","journal-title":"Qual. Life Res."},{"key":"243_CR42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00019053-200321030-00004","volume":"21","author":"TO Tengs","year":"2003","unstructured":"Tengs, T.O., Lin, T.H.: A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 21, 191\u2013200 (2003)","journal-title":"Pharmacoeconomics"},{"key":"243_CR43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1099-1050(200003)9:2<149::AID-HEC501>3.0.CO;2-N","volume":"9","author":"J Kirsch","year":"2000","unstructured":"Kirsch, J., McGuire, A.: Establishing health state valuations for disease specific states: an example from heart disease. Health Econ. 9, 149\u2013158 (2000)","journal-title":"Health Econ."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-010-0243-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-010-0243-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-010-0243-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T07:02:52Z","timestamp":1559113372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-010-0243-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,22]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1007\/s10198-010-0243-5","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,22]]}}}